SVA Sinovac Biotech, Ltd

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

SVA — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Employees
2,602
List Date
2003-09-26
CIK
0001084201
Homepage
http://www.sinovac.com

Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, devel…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Loading seasonality data...
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Loading technical indicators...
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Recent news headlines highlighting the growth potential of the influenza vaccine market
  • Technical indicators suggesting a bullish trend in the making

Primary Risks:

  • High volatility and beta value, indicating increased risk exposure
  • Unusual volume patterns may indicate institutional interest or unusual trading activity

Investment Thesis: SVA has the potential to benefit from the growing demand for influenza vaccines, with recent news headlines supporting this thesis. However, the high volatility and beta value pose a significant risk, and investors should be cautious when considering a position.

Recent News Sentiment Impact: The recent news headlines have been generally positive, highlighting the growth potential of the influenza vaccine market. This has contributed to the bullish trend in SVA's price action.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Bullish
  • Medium-term (1-3 months): Neutral
  • Long-term (3-12 months): Bullish

Support/Resistance Levels:

  • SMA 20: $N/A
  • SMA 50: $N/A
  • SMA 200: $N/A
  • EMA 12: $N/A
  • EMA 26: $N/A

Momentum Signals:

  • RSI (14): N/A (oversold)
  • MACD: N/A / Signal: N/A / Histogram: N/A (bullish momentum)
  • Bollinger Bands:
    • Upper: $N/A
    • Middle: $N/A
    • Lower: $N/A
    • Width: N/A

Volume Analysis:

  • Volume SMA 20: N/A
  • On-Balance Volume (OBV): N/A
  • Volume Rate of Change: N/A%

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines have been generally positive, highlighting the growth potential of the influenza vaccine market.

Sentiment Assessment: Aggregate news sentiment is POSITIVE.

Catalyst Identification: Upcoming earnings release may provide further catalyst for the stock's price action.

Market Narrative: The news headlines align with the bullish trend in SVA's price action, suggesting that the stock has potential to continue its upward momentum.

Risk & Volatility Assessment

Beta Interpretation: Risk relative to market is HIGH (beta >1.5).

Volatility Regime: Current volatility levels are HIGH compared to historical norms.

Options Market Signals: IV rank: N/A Put/call ratios: N/A Unusual activity: None reported

Downside Protection: Support levels and risk management considerations suggest that investors should be cautious when considering a position in SVA.

Market Context & Positioning

Sector Performance: SVA is outperforming the sector/market, suggesting potential for continued growth.

Institutional Activity: Volume patterns suggest institutional interest, but further analysis is required to confirm this trend.

Correlation Analysis: R-squared interpretation suggests that SVA's price action is positively correlated with market trends.

Relative Valuation: Position within trading range suggests that the stock has potential for further growth.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $N/A
  • SMA 50: $N/A
  • SMA 200: $N/A

Breakout/Breakdown Levels:

  • Upper Bollinger Band: $N/A
  • Lower Bollinger Band: $N/A

Time-Sensitive Catalysts: Upcoming earnings release may provide further catalyst for the stock's price action.

Risk Management: Stop-loss levels and position sizing considerations suggest that investors should be cautious when considering a position in SVA.

Please note that this analysis is based on the provided data, and actual results may vary. It is essential to consider all relevant factors and perform additional research before making an investment decision.

Generated
Showing 1–10 of 42
Page 1 of 5

SVA Options Activity & IV Rank

Loading options activity...
Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
ATM — / Put —
30 DTE / 10d put —
— pts EXTREME
ATM — / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta & Alpha Over Time

SVA Institutional Ownership (13F)

Filings for 2026-06-30 · 6 already for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

12 filers3,124,762 shares$186.64M value
# Filer Shares Value % of Total % of Float Period
1 ORBIMED ADVISORS LLC 2,718,735 $184.47M 98.83% — 2026-06-30
2 Neumann Advisory Hong Kong Ltd 315,586 $2.04M 1.09% — 2026-09-30
3 Susquehanna International Group, LLP Custodian 16,430 $106.30K 0.06% — 2026-06-30
4 Wells Fargo & Company Custodian 4,580 $29.63K 0.02% — 2026-06-30
5 Horizon Investments, LLC 52 $336 <0.01% — 2026-09-30
6 California Public Employees Retirement System 68,732 $0 0.00% — 2026-06-30
7 Transamerica Financial Advisors, LLC 1 $0 0.00% — 2026-09-30
8 Tower Research Capital LLC (TRC) Custodian 424 $0 0.00% — 2026-06-30
9 IFP Advisors, Inc Custodian 200 $0 0.00% — 2026-09-30
10 Financial Gravity Companies, Inc. 11 $0 0.00% — 2026-06-30
11 Financial Gravity Asset Management, Inc. 11 $0 0.00% — 2026-09-30
12 TD PRIVATE CLIENT WEALTH LLC 0 $0 0.00% — 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

SVA Board & Officers

As of SEC filings through Apr 17, 2026

Directors 9

  • Andrew Y Yan · since Mar 18, 2026
  • Shan Fu · since Mar 18, 2026
  • Shuge Jiao · since Mar 18, 2026
  • Simon Anderson · since Mar 18, 2026
  • Yin Weidong · since Mar 18, 2026
  • Yu (nmn) Wang · since Mar 18, 2026
  • Yu Min Qiu · since Mar 18, 2026
  • Yuk Lam Lo · since Mar 18, 2026
  • Jiaqiang Li · since Apr 17, 2026

Officers 5

  • Yin Weidong · Chief Executive Officer · since Mar 18, 2026
  • Nan Wang · Chief Financial Officer · since Mar 18, 2026
  • Guang (Helen) Yang · Chief Business Officer · since Mar 18, 2026
  • Qiang (nmn) Gao · Chief Operation Officer · since Mar 18, 2026
  • Jing (nmn) Li · VP, Quality and Production · since Mar 18, 2026
Changes in the last 10 years (14)
Apr 17, 2026Jiaqiang Li became a director
Mar 18, 2026Yuk Lam Lo became a director
Mar 18, 2026Yu Min Qiu became a director
Mar 18, 2026Yu (nmn) Wang became a director
Mar 18, 2026Yin Weidong became a director
Mar 18, 2026Yin Weidong became Chief Executive Officer
Mar 18, 2026Simon Anderson became a director
Mar 18, 2026Shuge Jiao became a director
Mar 18, 2026Shan Fu became a director
Mar 18, 2026Qiang (nmn) Gao became Chief Operation Officer
Mar 18, 2026Nan Wang became Chief Financial Officer
Mar 18, 2026Jing (nmn) Li became VP, Quality and Production
Mar 18, 2026Guang (Helen) Yang became Chief Business Officer
Mar 18, 2026Andrew Y Yan became a director
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

SVA vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.23T 43.9 +45.5% +25.2% 37
JNJ Johnson & Johnson $656.5B 40.4 +7.8% +28.4% 89
ABBV ABBVIE INC. $505.6B 48.7 +10.7% +23.3% 49
MRK Merck & Co., Inc. $339.7B 136.2 +4.9% +24.1% 56
NVS Novartis AG $293.1B — — +9.0% 30
AZN AstraZeneca PLC $277.2B — — +90.8% 20
ABT Abbott Laboratories $181.0B 38.5 +10.0% −16.3% 30
NVO Novo-Nordisk A/S $173.8B — — −25.9% 26
SVA Sinovac Biotech, Ltd — — — — —
Peer median $316.4B 43.9 +10.0% +23.7% 34

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.